Trending NewsTrending NewsNYSE:LLY Eli Lilly and Company (LLY) Stock Price, News & Analysis $1,258.04 +6.43 (+0.51%) Closing price 10/16/2026 03:59 PM EasternExtended Trading$1,256.50 -1.54 (-0.12%) As of 10/16/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Eli Lilly and Company Stock (NYSE:LLY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Eli Lilly and Company alerts:Sign Up Key Stats Today's Range$1,251.25▼$1,274.5650-Day Range$1,115.53▼$1,280.6252-Week Range$783.85▼$1,292.65Volume2.41 million shsAverage Volume2.30 million shsMarket Capitalization$1.18 trillionP/E Ratio39.92Dividend Yield0.55%Price Target$1,313.43Consensus RatingModerate Buy Company Overview Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health. The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease. Lilly also develops medicines for migraine, depression and other neurological conditions, and maintains a pipeline of treatments in clinical development. Founded in 1876 by Colonel Eli Lilly, the company is headquartered in Indianapolis, Indiana. Lilly serves patients and healthcare providers through operations and commercial activities in numerous countries worldwide. David A. Ricks is the company’s chair and chief executive officer.AI Generated. May Contain Errors. Read More Eli Lilly and Company Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks97th Percentile Overall ScoreLLY MarketRank™: 4.842983967135 of 5 starsEli Lilly and Company scored higher than 97% of companies evaluated by MarketBeat, and ranked 14th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.8 / 5Analyst RatingModerate Buy Consensus RatingEli Lilly and Company has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 24 buy ratings, 3 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Eli Lilly and Company is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageEli Lilly and Company has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Eli Lilly and Company's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth40.58% Earnings GrowthEarnings for Eli Lilly and Company are expected to grow by 40.58% in the coming year, from $33.56 to $47.18 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eli Lilly and Company is 42.22, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.33.Price to Earnings Ratio vs. SectorThe P/E ratio of Eli Lilly and Company is 42.22, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.22.Price to Earnings Growth RatioEli Lilly and Company has a PEG Ratio of 1.67. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEli Lilly and Company has a P/B Ratio of 44.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Eli Lilly and Company's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.75% of the float of Eli Lilly and Company has been sold short.Short Interest Ratio / Days to CoverEli Lilly and Company has a short interest ratio ("days to cover") of 2.93, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eli Lilly and Company has recently decreased by 6.44%, indicating that investor sentiment is improving significantly. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldEli Lilly and Company has a dividend yield of 0.55%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthEli Lilly and Company has been increasing its dividend for 11 years.Dividend CoverageThe dividend payout ratio of Eli Lilly and Company is 23.22%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Eli Lilly and Company will have a dividend payout ratio of 14.67% next year. This indicates that Eli Lilly and Company will be able to sustain or increase its dividend.Read more about Eli Lilly and Company's dividend. News and Social Media4.3 / 5News Sentiment0.90 News SentimentEli Lilly and Company has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 121 news articles for Eli Lilly and Company this week, compared to 10 articles on an average week.Search Interest144 people have searched for LLY on MarketBeat in the last 30 days. This is an increase of 38% compared to the previous 30 days.MarketBeat Follows121 people have added Eli Lilly and Company to their MarketBeat watchlist in the last 30 days. This is an increase of 64% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Eli Lilly and Company insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,958,170.00 in company stock.Percentage Held by Insiders0.14% of the stock of Eli Lilly and Company is held by insiders.Percentage Held by Institutions82.53% of the stock of Eli Lilly and Company is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Eli Lilly and Company's insider trading history. Receive LLY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eli Lilly and Company and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LLY Stock News HeadlinesEli Lilly & Co (LLY) Receives a Buy from RBC Capital44 minutes ago | theglobeandmail.comLilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress2 hours ago | prnewswire.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer.October 18 at 1:00 AM | Weiss Ratings (Ad)Can Eli Lilly’s (LLY) Growth Machine Keep Delivering?October 18 at 3:08 PM | finance.yahoo.comOnly 20 Stocks Are Holding Up the Market: 3 Bargains Outside AI (LLY)Stansberry Research's Whitney Tilson argues record highs mask a bifurcated market, favoring Joby Aviation, Casey's General Stores, and Eli Lilly as value picks outside the AI trade.October 15 at 5:43 PM | marketbeat.com3 Income Stocks Under $30 That Yield More Than the 10-Year Treasury Note (LLY)With the 10-year Treasury yielding around 5.3%, Pfizer, Energy Transfer, and Plains All American offer stocks under $30 with dividend yields between 6% and 7%.October 3, 2026 | marketbeat.com4 Stocks That Could Split Next—and Why Investors Are Watching (LLY)AutoZone, Eli Lilly, Meta Platforms, and Costco all trade at high share prices, making them candidates for stock splits as analysts raise price targets and cite strong fundamentals.September 30, 2026 | marketbeat.comMarketBeat Week in Review – 09/21 - 09/25 (LLY)A weekly roundup of MarketBeat analysis on volatile markets, oil, bond rates, AI stocks, dividend picks, and earnings outlooks, covering companies from NVIDIA to Tesla and Qualcomm.September 26, 2026 | marketbeat.comSee More Headlines LLY Stock Analysis - Frequently Asked Questions How have LLY shares performed this year? Eli Lilly and Company's stock was trading at $1,075.00 on January 1st, 2026. Since then, LLY shares have increased by 17.0% and is now trading at $1,258.0350. How were Eli Lilly and Company's earnings last quarter? Eli Lilly and Company (NYSE:LLY) released its earnings results on Wednesday, August, 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. The firm's revenue was up 47.7% compared to the same quarter last year. Read the conference call transcript. Is Eli Lilly and Company buying back stock? Eli Lilly and Company's Board of Directors authorized a share repurchase plan on Monday, December 9th 2024, which allows the company to buy back $15,000,000,000 in outstanding shares, according to EventVestor. This means that the company could buy up to 2% of its stock through open market purchases. Stock buyback plans are often an indication that the company's management believes its stock is undervalued. Does Eli Lilly and Company have any subsidiaries? Eli Lilly and Company subsidiaries include these companies: Protomer Technologies, Prevail Therapeutics Inc., Disarm Therapeutics, Disarm Therapeutics, Dermira, Loxo Oncology, CoLucid Pharmaceuticals, and more. Who are Eli Lilly and Company's major shareholders? Top institutional investors of Eli Lilly and Company include Sapient Capital LLC (0.16%), Assenagon Asset Management S.A. (0.08%), Goelzer Investment Management Inc. (0.06%) and Private Capital Advisors Inc. (0.04%). Insiders that own company stock include Lilly Endowment Inc, David A Ricks, Daniel Skovronsky, J Erik Fyrwald, Patrik Jonsson, Johna Norton, Anat Hakim, Jamere Jackson, Gabrielle Sulzberger and Donald A Zakrowski. View institutional ownership trends. How do I buy shares of Eli Lilly and Company? Shares of LLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eli Lilly and Company own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eli Lilly and Company investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Broadcom (AVGO), Micron Technology (MU), Johnson & Johnson (JNJ) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings8/05/2026Record date for 9/10 Dividend8/14/2026Ex-Dividend for 9/10 Dividend8/14/2026Dividend Payable9/10/2026Today10/18/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 LLY's financial health is in the Green zone, according to TradeSmith. LLY has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:LLY CIK59478 Webwww.lilly.com Phone(317) 276-2000Fax317-276-4878Employees50,000Year Founded1876Price Target and Rating Average Price Target for Eli Lilly and Company$1,313.43 High Price Target$1,600.00 Low Price Target$900.00 Potential Upside/Downside+4.4%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage29 Analysts Profitability EPS (Trailing Twelve Months)$29.80 Trailing P/E Ratio39.92 Forward P/E Ratio37.49 P/E Growth1.67Net Income$20.64 billion Net Margins33.53% Pretax Margin42.17% Return on Equity97.83% Return on Assets23.23% Debt Debt-to-Equity Ratio1.41 Current Ratio1.35 Quick Ratio1.00 Sales & Book Value Annual Sales$65.18 billion Price / Sales18.17 Cash Flow$25.16 per share Price / Cash Flow50.01 Book Value$28.07 per share Price / Book44.82Miscellaneous Outstanding Shares941,360,000Free Float940,039,000Market Cap$1.18 trillion OptionableOptionable Beta0.46 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NYSE:LLY) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredYour download link expires soonThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredElon Musk’s 4th Wealth Window Set to Open by October 30Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eli Lilly and Company Please log in to your account or sign up in order to add this asset to your watchlist. Share Eli Lilly and Company With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
